Incyte Corp
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
Did you know?
Holds 89.3x more cash than debt — a strong balance sheet.
Current Price
$96.91
+1.72%GoodMoat Value
$271.40
180.1% undervaluedProfile
Valuation (TTM)
Market Cap$19.29B
P/E13.47
EV$14.21B
P/B3.73
Shares Out199.01M
P/Sales3.60
Revenue$5.36B
EV/EBITDA8.18
Incyte Corp (INCY) — Earnings Call Transcripts
45 earnings call transcripts available.
Latest Transcript
Read →Q1 2026 Earnings Call
20 speakers7,542 words56 segments